Hims & Hers vs ShedRx: November 2026 prices compared
As of November 20, 2026, neither Hims & Hers nor ShedRx printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
Hims & Hers and ShedRx, measure by measure
| Measure | Hims & Hers | ShedRx |
|---|---|---|
| Tirzepatide, month to month | — | from $239 (lowest printed: "starting as low as"; no month-to-month figure) |
| Tirzepatide, lowest printed | — | $239 ("starting as low as") |
| Semaglutide, month to month | — | from $159 (lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure) |
| Semaglutide, lowest printed | — | $159 ("GLP-1s from $159/mo" (drug not named)) |
| Dose pricing | not confirmed | priced by dose or not stated |
| Membership or program fee | not confirmed | none |
| Computed score | not scored (brand route) | 12 of 40 (position 16 of 27) |
| FDA warning letters | 716567 (2025-09-09); 716825 (2025-09-09) | none listed |
| November 20 read | not readable Nov 20 | first-party read |
Strengths and limitations: which fits whom
Hims & Hers suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. ShedRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| ShedRx | tirzepatide | — | from $239 |
| ShedRx | semaglutide | — | from $159 |
Regulatory record
FDA’s warning-letter index lists warning letter 716567 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) and warning letter 716825 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Hims & Hers; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Hims & Hers or ShedRx?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do Hims & Hers and ShedRx charge a membership fee?
Hims & Hers: not confirmed on November 20, 2026; ShedRx: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Hims & Hers and ShedRx medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Hims & Hers pricing page (not readable on November 20, 2026)
- ShedRx pricing page (read November 20, 2026)
- FDA warning letter 716567 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)
- FDA warning letter 716825 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)